January 26, 2021

Medable Hires Parag Vaish as Chief Product Officer to Transform Clinical Trial Experience for Patients and Clinicians

No items found.




Save the Date!
Tuesday, January 26, 2021
2:45 pm

PALO ALTO, Calif. — Jan. 26, 2021 — Medable Inc, the leading cloud platform for patient-centered drug development, today announced the hiring of Parag Vaish as Chief Product Officer. Vaish is an established product leader with a strong track record transforming industries through product innovation. He has a unique background in healthcare and consumer markets, having served in product leadership roles at Tesla, Epocrates (part of athenahealth), and StubHub during critical phases in each company’s life cycle. Vaish also has prior experience at Google, NBC News, Microsoft and Disney.

As Medable continues to expand its product portfolio, Vaish brings valuable expertise creating products that are intuitive and enjoyable, removing friction from the user experience. During his tenure as head of digital product at Tesla, Vaish led a team of 43, dramatically changing how people buy the Tesla Model 3 through advance deposits, paperless transactions, and personalized home delivery. His team also built a payment system for in-car upgrades. At StubHub, Vaish and team led development of the award-winning StubHub mobile app, featuring a personalized, seamless experience that enabled users to buy tickets in just three taps. At Epocrates, Vaish evolved its mobile app from a 1.0 forms-based product to a modern 2.0 experience to help doctors minimize drug-to-drug interaction dangers.  

“Medable is creating a new category of enterprise software that will transform the clinical trial experience for patients, sites and sponsors, while using research data to drive breakthrough insights and massive improvements in drug development,” said Dr. Michelle Longmire, CEO and co-founder of Medable. “Parag brings the transformative thinking and product leadership that aligns with our disruptive vision.”

“As a product leader, I look to solve problems that radically advance industries,” said Vaish. “Medable’s vision to put patients at the center of clinical trials is exactly the type of product challenge that attracts me. As everyone knows, there’s a lot of friction, paperwork and inefficiency in the current process, which is intimidating to patients and cumbersome for clinicians. We’re excited to remove the complexity and reduce that friction, and in the process, help drive unprecedented advancement in life sciences.”

Vaish is also an accomplished author and speaker, having published two books on “Supercharging Diversity Hiring” (October 2020) and “Team Decision Matrix: How to Rank and Prioritize Nearly Anything” (February 2019).

Medable experienced record growth in 2020, with the launch of five new products, 50 new clients, 400 percent revenue growth, and $118 million in new funding. When COVID-19 struck, Medable helped customers quickly pivot away from in-person clinical trials so patients could remain at home. By minimizing the need for site visits, Medable customers have achieved unprecedented results – including 3X faster enrollment and over 90 percent retention rates.

For ongoing insight about decentralized trial adoption and patient-centered research, follow Medable via our blog, LinkedIn, Twitter and Facebook channels.

About Medable

Medable is on a mission to get effective therapies to patients faster by transforming clinical drug development with disruptive technologies. The company’s digital platform streamlines design, recruitment, retention and data quality for decentralized trials, replacing siloed systems with integrated digital tools, data and interfaces to accelerate trial execution. Medable connects patients, sites and clinical trial teams to improve patient access, experience, and outcomes. Medable is a privately held, venture-backed company headquartered in Palo Alto, California.


# # #


Media Contacts:

Lisa Barbadora, Big Valley Marketing for Medable, +1 (610) 420-3413, media@medable.com